Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties
- 2 March 1993
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 232 (2-3) , 139-145
- https://doi.org/10.1016/0014-2999(93)90767-c
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- The Antidepressant Effects of 5-HT Uptake InhibitorsThe British Journal of Psychiatry, 1989
- A Placebo-controlled Inpatient Comparison of Fluvoxamine Maleate and Imipramine in Major DepressionInternational Clinical Psychopharmacology, 1989
- Neuropharmacology of emesis induced by anti-cancer therapyTrends in Pharmacological Sciences, 1988
- Identification of 5-HT3 recognition sites in the ferret area postremaJournal of Pharmacy and Pharmacology, 1988
- Anorectic activities of serotonin uptake inhibitors: Correlation with their potencies at inhibiting serotonin uptake and 3H-mazindol bindingLife Sciences, 1988
- PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONISTThe Lancet, 1987
- Receptors in the gastrointestinal tractPharmacological Research Communications, 1987
- 5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesisNeuropharmacology, 1986
- Tissue 5‐hydroxytryptamine and urinary 5‐hydroxyindoleacetic acid after partial or total removal of the gastro‐intestinal tract in the ratThe Journal of Physiology, 1960